Novartis Oncology (China)
At Novartis Oncology, our mission is to enhance cancer and blood disorder patients’ quality of life, discover and develop breakthrough treatments and disease management methods, and find new ways to deliver them to as many people as possible. Headquartered in Basel, Switzerland, Novartis Oncology is a member of the Novartis Group, with over 10,000 associates in more than 85 countries.
Novartis Oncology has a strong presence in five key disease areas – breast cancer, lung cancer, melanoma, kidney cancer and hematology. We are reimagining medicine to transform cancer and blood disorders. We are the only pharmaceutical company with four distinct therapeutic platforms: targeted therapies, cell and gene therapy, immunotherapy and radioligand therapy. We currently have an unparalleled portfolio of therapies, with 25 drugs on the market and more than 30 new molecular entities in development targeting key molecular pathways in cancer biology.
In China, with over 1,100 associates, Novartis Oncology focuses on hematology, solid tumors and rare disease therapeutic areas, including chronic myelogenous leukemia (CML), myelofibrosis (MF), immune thrombopenia (ITP) and iron overload (IOL) in hematology, as well as breast cancer, lung cancer, kidney cancer and melanoma solid tumors, and rare diseases of gastrointestinal stromal tumors (GIST), acromegaly (ARCO) and neuroendocrine tumors (NET).
Patient health remains the first priority at Novartis. In China, we proactively comply with the government’s policies of innovation to speed up market access to new medicines. Since 2017, Novartis Oncology (China) has introduced between one and three new products or indications every year, bringing more target therapeutic treatments to the China market.
Novartis Oncology is not only satisfying patients’ unmet needs through research, development and the manufacture of innovative medicine. It is also proactively partnering with the government and third-party organizations, such as participating in National Reimbursement Drug List (NRDL) negotiations, accelerating market access, implementing innovative payment models, and conducting patient support programs and disease education, to improve patient access to innovative medicines in China. As of the end of December 2020, all 12 Novartis Oncology products marketed in China had been listed on the NRDL.